Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285777 · ClinicalTrials.gov registry record · Phase 2
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT02285777 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 189 participants.
The verdict
NCT02285777, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
This is extension of the V102\_16 study (NCT02140762). V102\_16E1 is designed to assess the effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6 month schedule, against the same panel of endemic US N. meningitidis serogroup B strains, as measured by enc-hSBA assay. The subjects who completed the parent V102\_16 study will be invited at the time of their last study visit to participate in this extension study.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Meningococcal ABCWY
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2014-12-01 |
| Est. Completion | 2015-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285777
The ClinicalTrials.gov registry entry for NCT02285777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02285777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02285777 about?
NCT02285777 is a clinical study titled "Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents". This is extension of the V102\_16 study (NCT02140762). V102\_16E1 is designed to assess the effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6 month schedule, against the same panel of endemic US N. meningitidis serogroup B strains, as measured by enc-hSBA as...
What is the current status of trial NCT02285777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2014-12-01. Estimated completion is 2015-06-11.
What interventions are being tested in trial NCT02285777?
The interventions under investigation include: Placebo (BIOLOGICAL), Meningococcal ABCWY (BIOLOGICAL).
Who is sponsoring clinical trial NCT02285777?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.